Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms21072275
Abstract: Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins… read more here.
Keywords: focus atherogenesis; vildagliptin focus; vildagliptin; effects vildagliptin ... See more keywords